NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/02/2026
Voltar para busca
Dado oficial do USPTO
MEIRAGTX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
MEIRAGTX
ST13
US500000099023559Classe
1, 5, 40, 42
Pedido
99023559
Registro
8140892
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
20
Atualização mais recente
17/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 40, 42
Data de depósito
30/01/2025
Data de registro
17/02/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/02/2026
Última transação
17/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
16
Localização do titular
London, GB
Examinador
REGAN, JOHN B
Unidade examinadora
M40
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
MeiraGTx Limited
Representantes
Michael J. Leonard Fox Rothschild LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
chemical additiveschemical auxiliary agentscarrierssubstancesall for use in the manufacture of pharmaceutical preparations
Classe 5
pharmaceutical products for use in gene therapy; pharmaceutical preparations and substances for the treatment of neurological and neurodegerative diseasesocular diseases and rare diseasesin the nature of rare kidney diseasesrare cardiovascular diseasesrare hepato-gastro-enterological diseasesrare immunodeficienciesdevelopmental defectsneuromuscular diseasesrare neurological diseasesrare cardiovascular diseasesrare lung diseasesrare bone diseasesrare sensory disordersrare skin diseasesrare diseases of connective tissuerare endocrine diseasesrare hereditary metabolic diseasesrare nonmalignant hematologic disordersalivary gland conditionsoncologyautoimmune conditionsageingmetabolic diseaseobesity; auxiliary agents for pharmaceutical preparationssmall molecule compounds for use as drug delivery agents in pharmaceuticals; carriers for pharmaceutical preparationsdrug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals; substances for pharmaceutical preparationsanti-infectivesanti-inflammatoriesantibacterial pharmaceuticalsantibioticsantifungal preparationsantivirals; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; dermatological pharmaceutical preparations and substances; pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations and substances for ophthalmological use; pharmaceutical preparations and substances for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations and substances for the prevention and treatment of bone diseasessalivary gland conditionsoncologyautoimmune conditionsagingmetabolic diseaseobesity; biological preparations for use in cell cultures for medical purposes
Classe 40
Custom manufacture of human therapeuticspharmaceuticalsbiologicals and biopharmaceuticals
Classe 42
scientific research in the field of geneticsgene therapy and genetic engineering; genetic testing for scientific research purposes; scientific advisory services relating to gene therapy research; scientificbiologicalpharmaceutical and medical research services; laboratory research in the fields of geneticsdrug developmentbiotechnologymicrobiology and molecular biology; biochemical and biotechnological analysis services
Publicações
Histórico de despachos e eventos da marca no USPTO.
20 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
17/02/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/12/2025
PUBO
PUBLISHED FOR OPPOSITION
30/12/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/12/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/12/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
10/11/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/11/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
10/11/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/11/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/10/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/10/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/10/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/07/2025
GNRT
NON-FINAL ACTION E-MAILED
21/07/2025
CNRT
NON-FINAL ACTION WRITTEN
21/07/2025
DOCK
ASSIGNED TO EXAMINER
10/07/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/07/2025
NWAP
NEW APPLICATION ENTERED
30/01/2025
MAFR
APPLICATION FILING RECEIPT MAILED
30/01/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MEIRAGTX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.